Invasive management of renal cell carcinoma in von Hippel-Lindau disease.

Autor:	Carrion DM; Department of Urology, La Paz University Hospital, Madrid, Spain Autonomous University of Madrid, Madrid, Spain., Linares-Espinós E; Department of Urology, La Paz University Hospital, Madrid, Spain Autonomous University of Madrid, Madrid, Spain.; La Paz University Hospital, Institute for Health Research (IdiPAZ), Madrid, Spain., Ríos González E; Department of Urology, La Paz University Hospital, Madrid, Spain Autonomous University of Madrid, Madrid, Spain.; La Paz University Hospital, Institute for Health Research (IdiPAZ), Madrid, Spain., Bazán AA; Department of Urology, La Paz University Hospital, Madrid, Spain Autonomous University of Madrid, Madrid, Spain.; La Paz University Hospital, Institute for Health Research (IdiPAZ), Madrid, Spain., Alvarez-Maestro M; Department of Urology, La Paz University Hospital, Madrid, Spain Autonomous University of Madrid, Madrid, Spain.; La Paz University Hospital, Institute for Health Research (IdiPAZ), Madrid, Spain., Martinez-Pineiro L; Department of Urology, La Paz University Hospital, Madrid, Spain Autonomous University of Madrid, Madrid, Spain.; La Paz University Hospital, Institute for Health Research (IdiPAZ), Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Central European journal of urology [Cent European J Urol] 2020; Vol. 73 (2), pp. 167-172. Date of Electronic Publication: 2020 May 20.
DOI:	10.5173/ceju.2020.0004
Abstrakt:	Introduction: Patients affected by von Hippel-Lindau (VHL) disease experience an increased risk for bilateral, synchronous, and metachronous renal cell carcinoma (RCC). Oncologic and functional outcomes are the main goals in the management of renal masses. We present our protocol for patients with VHL disease-associated RCC alongside functional and oncologic results observed in our series. Material and Methods: We performed a retrospective analysis of our clinical database of patients with VHL disease-associated RCC referred to our department between June 2005 and December 2017. We offer surveillance for lesions <2 cm and active management with radiofrequency ablation (RFA) for lesions 2-3 cm, and nephron-sparing surgery (NSS), RFA or embolization techniques for lesions >3 cm or growth rate >1 cm/year. Results: Our series comprises 14 patients, of whom 13 had undergone at least one invasive procedure for RCC, mean age at first intervention was 27 years (range 18-60). Overall, 30 interventions were performed in 21 kidneys: four radical nephrectomies, 13 RFAs, 12 NSSs, and one embolization. During follow-up (median time: 41 months, range: 6-149), eight patients (57%) presented with new lesions that required treatment, with a mean time between treatments of 32 ±18.5 months. No metastatic progression or need for dialysis was recorded; the success rate for RFA was 85%. Conclusions: Management of VHL kidney disease by NSS is the standard of care with a cut-off at 3 cm, ablative procedures should be offered to lesions ranging 2-3 cm in size. Follow-up should be done strictly in referral centers that can provide all treatment options to renal function and control oncologic progression. Competing Interests: The authors declare no conflicts of interest. (Copyright by Polish Urological Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu